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Purpose
The purpose of this scoping review is to identify currently
available literature on utilizing dexmedetomidine
(Precedex) to reduce perioperative opioid use and
postoperative nausea and vomiting (PONV).

Methods-continued
Inclusion criteria:
➢ Use of dexmedetomidine and its effect on PONV
➢ Adult patients

Exclusion criteria:
➢ Pediatric patients
➢ Articles without full text
➢ Articles not in English

Background
➢ PONV is a problem that occurs in 30-80% of patients
undergoing elective surgery.
➢ PONV is linked to costly postoperative complications
and patient dissatisfaction.

Critical Appraisal:
➢ 8 articles met all criteria and were appraised

➢ Dexmedetomidine (Precedex) is an alpha-2
adrenoreceptor agonist that is used for anxiolysis,
sedation, and analgesia.
➢ Dexmedetomidine has been shown to independently
reduce PONV and opioid requirements, but evidence
supporting these modalities is not well-documented.

➢ Search engines: PubMed, OVID, CINAHL
➢ Over 11,000 articles initially returned

➢The practice of using two classes of antiemetics to
prevent PONV remains the standard of care in
anesthetic practice, making some providers hesitant to
attempt using dexmedetomidine for this purpose.
➢Providers should be educated on the findings of this
scoping review.
➢Further studies aiming to identify the efficacy of using
dexmedetomidine to reduce PONV should be
conducted.
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➢ There are many available treatment protocols that aim
to reduce PONV, yet it remains a problem.

Scoping review:

➢Dexmedetomidine is effective for reducing
perioperative opioid usage and PONV.

Results

➢ There are numerous anesthesia-related causes of
PONV, and opioids are one of the most potent
offenders.

Methods

Implications for Practice

Incorporation of dexmedetomidine, an alpha-2
agonist, in an opioid-sparing approach
significantly reduced incidences of PONV and
postoperative pain scores

